| Peter Charles Grosso, MD | |
|
1005 Commercial Lane, Godwin Bldg On Rt 10, Suite 220, Suffolk, VA 23434-8149 | |
| (757) 668-2600 | |
| (757) 668-2620 |
| Full Name | Peter Charles Grosso |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 1005 Commercial Lane, Suffolk, Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144286832 | NPI | - | NPPES |
| 890583W | Medicaid | NC | |
| 6746209 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 0101042222 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Peter Charles Grosso, MD 1005 Commercial Lane, Godwin Bldg On Rt 10, Suite 220, Suffolk, VA 23434-8149 Ph: (757) 668-2600 | Peter Charles Grosso, MD 1005 Commercial Lane, Godwin Bldg On Rt 10, Suite 220, Suffolk, VA 23434-8149 Ph: (757) 668-2600 |
News Archive
A study recently published in the journal Matter has demonstrated the development and validation of a nanoparticle-based formulation, capable of completely inhibiting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection blocking the interaction between viral spike protein and host cell angiotensin-converting enzyme 2 (ACE2).
A study reports an important discovery about abdominal aortic aneurysms that could help to identify high-risk patients who need to be monitored more closely.
A research team led by Dr. Nada Jabado at the MUHC Research Institute and Dr. Jacek Majewski at McGill University has proven for the first time that it is possible to identify any genetic disease in record time thanks to a powerful and reliable exome sequencing method. The exome, a small part of the genome ((less than) 2%), is of crucial interest with regard to research on genetic diseases as it accounts for 85% of mutations.
Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin™ (bevacizumab – Genentech/Roche) in a preclinical model of breast cancer. At the same time the Company announced that it has developed a new High Throughput Screening (HTS) platform for the identification of small molecule inhibitors of protein ubiquitination, a key element in the essential cellular process of protein homeostasis, which is an exciting new target pathway for cancer treatment. Both scientific developments will be presented as posters at the EACR conference in Barcelona Spain on July 7-10 2012.
› Verified 3 days ago
Jessica Saxbury, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 3060 Godwin Blvd, Suffolk, VA 23434 Phone: 757-923-9660 Fax: 757-923-9665 | |
Dr. Nellie M Sankaran, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 440 W Washington St, Suffolk, VA 23439 Phone: 757-539-4822 Fax: 757-925-0346 | |
Dr. Jane Melinda Robertson, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1009 Hillpoint Blvd., Suffolk, VA 23434 Phone: 757-668-2250 Fax: 757-668-2255 | |
Ms. Brittney S Drames, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1009 Hillpoint Blvd N, Suffolk, VA 23434 Phone: 757-668-2250 Fax: 757-668-2255 | |
Dr. Laura Schuetz Wright, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 4868 Bridge Rd, Suffolk, VA 23435 Phone: 757-483-7113 Fax: 757-483-7151 | |
Douglas Blair Gregory, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 4868 Bridge Road, Suffolk, VA 23435 Phone: 757-483-7900 Fax: 757-483-7151 |